WASHINGTON DC: Glaxo Wellcome has handed a six-figure assignment to
promote its new irritable bowel syndrome (IBS) treatment Lotronex to
Fleishman-Hillard. Marilyn Castaldi, senior partner and director of
F-H’s healthcare practice, said the agency aims to raise consumer
awareness of IBS and the fact that it can be easily treated. She added
that F-H’s efforts, split between New York and Washington, will mainly
target women, who are more commonly affected by IBS than men.